Lung Cancer Prognosis Market Global Trends, Industry Analysis and Forecast up to 2025

Share this news:

Lung Cancer Prognosis Market research report is a global study offering rich insights on market forecasts, latest market trends, market competition, and opportunity analysis.

Stratview Research announces the launch of a new research report on the Lung Cancer Prognosis Market by Epidemiology, By Treatment Algorithm in Different Regions, By Procedures (Thoracotomy (Lobectomy, Pneumonectomy, and Segmentectomy), Minimally Invasive), By Device (Surgical (Clamps, Forceps, Retractors, Others and by Monitoring Devices - Camera, Trocar and Endoscopic Instrument) and by Region (North America, Western Europe, Asia-Pacific, Latin America, Rest of the World)

This report, from Stratview Research, studies the global lung cancer prognosis over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.

Lung Cancer Prognosis The Global Lung Cancer Management Market in 2019
For the first time in market, one report exclusively touches upon the demands, gaps and opportunities of the global lung cancer market while covering Lung Cancer Diagnostics, Lung Cancer Therapeutics, Lung Cancer Nutritional supplement, Lung Cancer Surgery and Lung Cancer Connected Health Market. The management of Lung cancer varies with region, by decision makers, by site of treatment, by type of lung cancer, by age, by decision making process, by cost of therapy at each stage and by various other parameters. Why Lung Cancer? Because WHO and other health agencies consider it to be the number One killer across the world.

If we consider the Lung Cancer Management Market from the stakeholder s perspective, then drugs approved for Small Cell Lung Cancer will not be applicable for Non-Small Cell Lung Cancer. What is the future of the top 10 best-selling drugs in this segment, will they stay or fade away? Among the class of drugs, will Angiogenesis Inhibitors take a dip in sales by 2025 or will it overtake the sales of drugs in the class Immune Checkpoint Inhibitors? What is the market for BRAF / MEK Inhibitors? Who all are the active players and who are newbies. Will the differential cost of therapeutics across the regions impact the drug sales in North America versus APAC? In the Small Scale Lung Cancer Therapeutics, immunotherapy drugs will play a major role in the next 7 years and may grow a CAGR of 7.44% globally however the same class of drugs might grow at a CAGR of 10.59% in the Non-Small Scale Lung Cancer Therapeutics Market in the same time period.

Click here to request the detailed TOC of the report:-
https://www.stratviewresearch.com/toc/425/lung-cancer-prognosis-market.html
OR
Request a sample here:-
https://www.stratviewresearch.com/Request-Sample/425/lung-cancer-prognosis-market.html

Considering that all the drugs mentioned above have a bright future till 2025, how many companies would like to compete in this market. How will the new joiners react if they consider that the market had a potential of USD 17.11 Billion alone in 2018 and is likely to grow at a CAGR of 8.28% globally till 2025.

In the Lung Cancer Diagnostics segment, Thermofischer, Roche, Biomerieux are few of the market leaders but are they going to get tougher competitions from the newbies such as Astraeus Technologies, Zebra Medical, Deton, Oncocyte and many more that are entering the specialized diagnostics market. It might be interesting to consider that while 50% of the oncologists decide (decision makers) the type of tests and the frequency of repeat tests, shared decision making process is equally high among the Lung Cancer Management Market. The opportunity is huge, NSCLC cases accounts for 85% of the recorded lung cancer incidence worldwide, > 60% require diagnosis, medicine for maintenance, pain and other side effects.

Considering the complications and limitations in lung cancer surgery (not all patients are eligible), still the market is expected to grow steadily at a CAGR of 6.29%, over the course of forecast period (2019-2025). The demand for NSCLC surgery is high, thus the market size of 99%. In some cases surgery is not recommended, when the tumor is found in proximity with the heart, the esophagus the food pipe, the wind pipe and major blood vessels. The demand for NSCLC surgery is expected to grow rapidly with a CAGR of 6.31% over the course of seven years. The study on the Lung Cancer Management Market by Stratview also states that Lobectomy (sub segment under Lung Cancer Surgery) results in lowest recurrence rate and higher survival rate as compared to other surgery type. Hence it is the highly referred type of surgery procedure for NSCLC cases. One of the companies, Auris is most promising in this segment and has a brighter future ahead. This segment also foresees competition from Chinese companies such as IFLYTEK who are strong contenders in the global market.

The Global Lung Cancer Prognosis Market is segmented into the following categories:
By Treatment Algorithm
APAC
North America
Western Europe
Rest of The World
By Demand & Supply
Import
Export
By Device
Surgical (Clamps, Forceps, Retractors, Others)
Monitoring Devices (Camera, Trocar and Endoscopic Instrument)
By End-User
Decision Maker
Decision Making Process
By Region
North America (Country Analysis: the USA, Canada)
Western Europe (Country Analysis: Germany, France, the UK)
Asia-Pacific (Country Analysis: China, Japan, India, and Rest of Asia-Pacific)
Latin America (Country Analysis: Brazil, Argentina, Mexico, and Others)
Rest of the World (Sub-Region Analysis: The Middle East, Africa, Rest of Europe and Others)

Stratview Research has several high value market reports in the healthcare & life science industry. Please refer to the following link to browse through our reports:
https://www.stratviewresearch.com/market-reports/Healthcare-and-Life-Sciences.html

Contact Info:
Name: Aditya Joshi
Email: Send Email
Organization: Stratview Research
Website: https://www.stratviewresearch.com

Release ID: 486696

CONTACT ISSUER
Name: Aditya Joshi
Email: Send Email
Organization: Stratview Research
SUBSCRIBE FOR MORE